The government has okayed the Health Ministry acceptance of stocks of coronavirus drug remdesivir from Gilead Sciences.
The drug is widely viewed as the most promising treatment available today. It is not clear how many doses Israel will be receiving.
In May, Asher Shalmon, the Health Ministry’s director of international relations, told The Times of Israel that Israel’s strong relationship with the California-based Gilead put the country in a good position to ensure supply.
A vial of the drug remdesivir is viewed during a press conference about the start of a study with the drug in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, April 8, 2020, amidst the coronavirus pandemic. (Ulrich Perrey / POOL / AFP)
“We have a long-lasting relationship with the company, they have strong representation here, and this helps in making sure it is available here,” he said.
Israeli hospitals were part of two studies into remdesivir’s effectiveness. The drug helped save the country’s first seriously ill patient, an East Jerusalem bus driver in his 30s, according to the Health Ministry.
Israel is also stockpiling hydroxychloroquine, though studies have shown it to be dangerous when given to COVID-19 patients.
Animal lovers, this one's for you
In 1935, Rabbi Max Shorenstein left Denmark to pursue his lifelong dream: building a zoo in Tel Aviv and teaching children to love animals. The Tel Aviv Zoo became one of the city’s greatest attractions, but envy, greed, and corruption drove Shorenstein from the paradise he created.
The film 'There Are No Lions in Tel Aviv' is available to screen November 19-26 for members of our reader support group, The Times of Israel Community. Join the Community todayto support our work and watch our DocuNation series of outstanding Israeli documentary films.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel